Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

After its $1 billion acquisition by Novartis, Mariana Oncology is expanding its Massachusetts real estate. Biotech's Future - ...

During the trial, none of the participants needed blood transfusions, and 92.7% of them reached Hb levels of at least 12g/dL.

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

As per reports, the legal battle between Novartis and MSN is expected to move to the next patent, which expires in November ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the ...

Novartis AG has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of familial dysautonomia, Huntington’s disease and spinal muscular atrophy.

In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of ...

Novartis has unveiled further data for Fabhalta (iptacopan), reinforcing its position in the paroxysmal nocturnal ...